% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Aarsland:285022,
      author       = {Aarsland, Dag and Sunde, Anita Lenora and Tovar-Rios, Diego
                      A and Leuzy, Antoine and Fladby, Tormod and Zetterberg,
                      Henrik and Blennow, Kaj and Tan, Kübra and De Santis,
                      Giovanni and Yakoub, Yara and Arslan, Burak and Huber, Hanna
                      and Pola, Ilaria and Grötschel, Lana and Di Molfetta,
                      Guglielmo and Skjellegrind, Håvard K and Selbaek, Geir and
                      Ashton, Nicholas J},
      title        = {{P}revalence of {A}lzheimer's disease pathology in the
                      community.},
      journal      = {Nature},
      volume       = {650},
      number       = {8100},
      issn         = {0028-0836},
      address      = {London [u.a.]},
      publisher    = {Nature Publ. Group},
      reportid     = {DZNE-2026-00147},
      pages        = {182 - 186},
      year         = {2026},
      abstract     = {The prevalence of Alzheimer's disease neuropathological
                      changes (ADNCs), the leading cause of cognitive impairment,
                      remains uncertain. Recent blood-based biomarkers enable
                      scalable assessment of ADNCs1. Here we measured
                      phosphorylated tau at threonine 217 in 11,486 plasma samples
                      from a Norwegian population-based cohort of individuals over
                      57 years of age as a surrogate marker for ADNCs. The
                      estimated prevalence of ADNCs increased with age, from less
                      than $8\%$ in people 58-69.9 years of age to $65.2\%$ in
                      those over 90 years of age. Among participants aged 70 years
                      or older, $10\%$ had preclinical Alzheimer's disease,
                      $10.4\%$ had prodromal Alzheimer's disease and $9.8\%$ had
                      Alzheimer's disease dementia. Furthermore, among those 70
                      years of age or older, ADNCs were present in $60\%$ of
                      people with dementia, in $32.6\%$ of those with mild
                      cognitive impairment and in $23.5\%$ of the cognitively
                      unimpaired group. Our findings suggest a higher prevalence
                      of Alzheimer's disease dementia in older individuals and a
                      lower prevalence of preclinical Alzheimer's disease in
                      younger groups than previously estimated2.},
      keywords     = {Humans / Alzheimer Disease: epidemiology / Alzheimer
                      Disease: pathology / Alzheimer Disease: blood / Alzheimer
                      Disease: diagnosis / Aged / Prevalence / Aged, 80 and over /
                      Male / Female / tau Proteins: blood / tau Proteins:
                      chemistry / Norway: epidemiology / Cognitive Dysfunction:
                      epidemiology / Cognitive Dysfunction: blood / Cognitive
                      Dysfunction: pathology / Middle Aged / Phosphorylation /
                      Cohort Studies / Biomarkers: blood / Age Factors / tau
                      Proteins (NLM Chemicals) / Biomarkers (NLM Chemicals)},
      cin          = {AG Schneider},
      ddc          = {500},
      cid          = {I:(DE-2719)1011305},
      pnm          = {353 - Clinical and Health Care Research (POF4-353)},
      pid          = {G:(DE-HGF)POF4-353},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:41407852},
      doi          = {10.1038/s41586-025-09841-y},
      url          = {https://pub.dzne.de/record/285022},
}